Analysis of Exalenz Bioscience manpower and management performance can provide insight into Exalenz Bioscience stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Exalenz Bioscience future performance. Additionally see Investing Opportunities.
Exalenz Bioscience Management EffectivenessThe company has return on total asset (ROA) of (24.33) % which means that it has lost $24.33 on every $100 spent on asset. This is way below average.
Exalenz Bioscience Workforce Comparison
Exalenz Bioscience Ltd is one of the top stocks in number of employees category among related companies. The total workforce of Diagnostics & Research industry is currently estimated at about 34.0. Exalenz Bioscience totals roughly 17.0 in number of employees claiming about 50% of equities under Diagnostics & Research industry.
Exalenz Bioscience Profit MarginsThe company has Profit Margin (PM) of (34.07) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (36.78) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.37.
Exalenz Bioscience Stakeholders
|Uri Geiger Chairman of the Board|
|Susan Alpert Vice President of Regulation|
|Ari Soae Vice President-Supply Chain|
|Eitan Blank Vice President - Operations|
|Nisim Bilman Vice President - Research & Development|
|Michal Hershkovitz Vice President-Regulation & Quality Assurance|
|Ofer Schlesinger Vice President - Research & Development|
|Mark Hod Vice President of Sales, North America|
|Roy Golan President Vice President - Finance|
|David Stolick CFO|
|Raphael Werner COO|
|Ilan Oren CTO|
|Nachum Shamir Director|
|Shmuel Rubinstein Director|
|Saul Yemal External Director|
|Avi Zigelman External Director|
|Itai Arkin Director|
|Sharon Kochan External Director|
|Gad Keren External Director|
|Menachem Inbar Director|
|Einat Zisman Director|
|Niza Lipshitz External Director|
Exalenz Bioscience employes about 17 people. The company is managed by 22 executives with total tenure of roughly 132 years, averanging almost 6.0 years of service per executive having 0.0 employee per reported executive.
|Revenue Per Employee||754.1 K|
|Revenue Per Executive||582.7 K|
|Net Loss Per Employee||257.1 K|
|Net Loss Per Executive||198.6 K|
|Working Capital Per Employee||1.5 M|
|Working Capital Per Executive||1.2 M|